Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

Go back to Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

Savara (SVRA) Tops Q3 EPS by 10c

November 7, 2019 5:41 PM EST

Savara (NASDAQ: SVRA) reported Q3 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).

Based on the totality of evidence, we continue to believe that Molgradex has a clinically meaningful treatment effect on aPAP and we are committed to this program, said Rob Neville, Chief... More